Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Initial data from study expected in first quarter 2023 ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis…


The product has been added to your cart.

Continue shopping View Cart